Burosumab-twza Price in India: What Determines the Overall Treatment Cost?
 |
| Buy burosumab-twza injection in India |
For patients and families managing rare disorders such as X-linked hypophosphatemia (XLH) or tumor-induced osteomalacia (TIO), the cost of treatment can be an important consideration. Burosumab-twza, marketed as Crysvita, is a targeted therapy designed to address the underlying FGF23-driven phosphate imbalance associated with these conditions.
However, there is no single fixed burosumab-twza price in India that applies to every patient. The overall amount depends on several factors, including the prescribed dose, treatment frequency, international sourcing, import-related expenses, taxes, documentation, shipping and currency exchange rates.
What is Burosumab-twza?
Burosumab-twza is a recombinant human monoclonal IgG1 antibody that targets and inhibits fibroblast growth factor 23 (FGF23). By inhibiting excess FGF23, it helps restore phosphate balance and support bone health.
Crysvita is supplied as a subcutaneous injection in single-dose vials available in 10 mg/mL, 20 mg/mL and 30 mg/mL strengths.
The treatment is indicated for XLH in patients aged 6 months and older and for TIO in patients aged 2 years and older when the underlying phosphaturic mesenchymal tumor cannot be located or surgically removed.
Why the Burosumab-twza Price in India Can Vary
Unlike medicines that are routinely stocked through standard retail pharmacy channels, the supplied information describes Burosumab as a prescription-only medicine that is not available through conventional pharmacy or standard pharmaceutical distribution channels. Pricing therefore depends on the circumstances of individual procurement and importation.
Several Components Can Influence the Final Treatment Cost.
1. Prescribed Dose and Treatment Frequency
The amount of Burosumab required is one of the most important factors affecting treatment expenditure. Dosing is determined according to the patient's body weight, age, condition and response to treatment.
For pediatric patients with XLH weighing 10 kg or more, the recommended starting dose is 0.8 mg/kg every two weeks, rounded to the nearest 10 mg, with adjustments possible depending on serum phosphorus levels. For children weighing less than 10 kg, the starting dose is 1 mg/kg every two weeks.
For adults with XLH, the recommended dose is 1 mg/kg every four weeks, rounded to the nearest 10 mg, with a maximum dose of 90 mg.
Pediatric TIO has a different dosing schedule, beginning at 0.4 mg/kg every two weeks and allowing dose increases when clinically appropriate, up to a maximum of 180 mg every two weeks.
As the quantity needed differs between patients, the medicine cost cannot be estimated accurately from the product name alone.
2. Product Strength and Number of Vials Required
Crysvita is available in 10 mg/mL, 20 mg/mL and 30 mg/mL single-dose vials.
The prescribed dose determines which strength or combination of vials is required. Since the vials are intended for single-dose use and unused medicine must be discarded, the number of vials required for each administration can also influence the overall expenditure.
3. International Supplier Access
The price can also depend on where the medicine is sourced. The available information identifies supplier access and availability from international manufacturers as factors that can influence the price in India. Country of origin can also affect the final amount.
This means that two quotations obtained at different times may not necessarily be identical, even when the prescribed dose remains unchanged.
4. Import Regulations and Documentation
When Burosumab needs to be sourced internationally, regulatory and documentation requirements form another part of the process.
The documentation described for named-patient import includes a valid prescription containing the medicine name, dosage, treatment duration and diagnosis, along with relevant medical records and patient identification documents. An import permit may also be required.
The Crysvita documentation additionally lists details such as the prescribing doctor's signature and stamp, registration number, required quantity and patient identification proof.
These requirements are important not only for regulatory compliance but also for determining the actual process and associated costs of obtaining the medicine.
5. GST and Other Local Taxes
Local taxes can contribute to the final amount paid by the patient. The supplied information specifically identifies GST and other local taxes among the factors that may affect the price of Burosumab in India. Consequently, the medicine's international procurement price should not automatically be treated as the patient's final cost in India.
6. Shipping and Cold-Chain Logistics
Burosumab requires refrigerated storage at 2°C to 8°C and must be protected from light in its original carton. It should not be frozen or shaken. For imported shipments, the documentation specifies delivery in a validated cold-chain box. Cold-chain handling can therefore be an important component of the overall cost, particularly when the medicine is transported internationally. Shipping charges are specifically identified as one of the factors contributing to total treatment expenditure.
7. Currency Exchange Rates
Since international procurement may involve payment to overseas suppliers, fluctuations in currency exchange rates can affect the final price in India. The available pricing information specifically identifies exchange rates as a factor influencing the total cost.
As a result, an earlier quotation may not remain unchanged if exchange rates or international procurement conditions shift.
Why a Quotation May Be Provided After Reviewing Medical Documents
As Burosumab dosing depends on patient-specific factors and its supply may involve international procurement, a generalized price does not necessarily represent the actual cost for a particular patient.
The available information indicates that a price quotation can be provided after reviewing a valid medical prescription and relevant medical documents. This approach allows the required strength, dosage, quantity, treatment duration and import requirements to be considered before determining the applicable quotation.
What Patients Should Consider Beyond the Medicine Price
When comparing the cost of Burosumab-twza, patients and caregivers should look beyond the listed price of the vial. The overall treatment expenditure may include:
The required dose and number of vials
Frequency of administration
International procurement and supplier access
Country of origin
Import-related requirements
Documentation and coordination
Applicable GST and other local taxes
International and domestic shipping
Cold-chain transportation
Currency exchange fluctuations
The source material specifically notes that total cost depends on shipping charges, country of origin, documentation fees and exchange rates in addition to market and regulatory factors.
Understanding the Import Pathway for Burosumab in India
For patients who need to obtain Burosumab through an international supply route, the process begins with submission of the medicine request, prescription and treatment information. The described pathway then involves Form 12A, document verification, regulatory approval, procurement through licensed international suppliers, and delivery to the patient's address.
Orders are processed after the required documents have been submitted and verified, with sourcing taking place through an authorized global distributor once the relevant approval is obtained.
For patients and caregivers, understanding this process can help set realistic expectations about both timelines and costs.
Choosing a Reliable Source for Burosumab-twza
As Crysvita requires controlled storage and international sourcing may be involved, supplier credentials and handling practices are important considerations.
The product information recommends selecting suppliers that hold a valid Good Distribution Practice (GDP) certificate and a valid operating licence, reflecting appropriate standards for pharmaceutical distribution.
Patients should also ensure that the medicine is transported under appropriate cold-chain conditions and that the required regulatory and prescription documentation is in place.
Final Thoughts on Burosumab-twza Treatment Cost in India
The Burosumab-twza price in India is not determined by the medicine's international purchase price alone. Patient-specific dosing, vial requirements, treatment frequency, supplier availability, country of origin, import requirements, taxes, documentation, shipping, cold-chain logistics and currency exchange rates can all contribute to the final treatment cost.
For this reason, patients considering Crysvita should obtain a quotation based on their prescription, required dosage, treatment duration, and quantity, rather than relying on a generic price estimate. Most importantly, Burosumab should be obtained through an appropriate prescription and compliant supply pathway so that the medicine's authenticity, quality and required storage conditions can be maintained throughout the process.
